Plasma Exosomal MicroRNA-125b As a Monitoring Biomarker of Resistance to MFOLFOX6-based Chemotherapy in Advanced and Recurrent Colorectal Cancer Patients

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2019 Sep 10

PMID 31497299

Citations 27

Authors

Takahiro Yagi

Hisae Iinuma

Tamuro Hayama

Keiji Matsuda

Keijirou Nozawa

Mitsuo Tsukamoto

Ryu Shimada

Takuya Akahane

Takeshi Tsuchiya

Tsuyoshi Ozawa

Yojiro Hashiguchi

Affiliations

Soon will be listed here.

Abstract

Liquid biomarkers for the early detection of resistance to chemotherapy are important for improving prognosis. This study investigated the usefulness of plasma exosomal microRNA-125b (ex-miRNA-125b) for the early detection of resistance to modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)-based first-line chemotherapy in patients with advanced or recurrent (advanced/recurrent) colorectal cancer (CRC). First, ex-miRNAs associated with resistance to mFOLFOX6-based chemotherapy were profiled via miRNA microarray analysis. In this analysis, ex-miR-125b exhibited the greatest upregulation in patients with progressive disease (PD) compared with the findings for patients with stable disease (SD) and healthy controls. Next, another 55 patients with advanced/recurrent CRC who received mFOLFOX6-based first-line chemotherapy underwent a validation study of ex-miR-125b. Blood samples were collected before and during treatment until tumor progression. Ex-miRNA levels were measured via TaqMan microRNA assays. Patients with CRC had significantly higher ex-miR-125b levels than healthy controls. In patients with partial responses, ex-miR-125b levels at the Response Evaluation Criteria in Solid Tumors (RECIST) judgment point were significantly lower than those measured before treatment. In patients with SD, ex-miR-125b levels did not differ before and during treatment. In patients with PD, ex-miR-125b levels at the RECIST judgment point were significantly higher than those measured before treatment. These changes in ex-miR-125b levels were significantly different between groups even 1 month after the initiation of chemotherapy. Progression-free survival (PFS) was significantly worse in patients with high baseline ex-miR-125b levels than in those with low levels. In the Cox analysis, baseline ex-miR-125b levels and KRAS mutation were indicated to be independent prognostic factors for PFS. The present results suggest that plasma ex-miR-125b levels may be useful for the early detection of resistance to mFOLFOX6-based first-line chemotherapy. Furthermore, ex-miR-125b before chemotherapy is a predictive biomarker for PFS in patients with advanced/recurrent CRC.

Citing Articles

Circulating exosome-derived miR-191-5p is a novel therapeutic biomarker for radiotherapy in esophageal squamous cell carcinoma patients.

Wang H, Matsumoto Y, Maiyulan A, Toyozumi T, Otsuka R, Sekino N Esophagus. 2025; .

PMID: 40064799 DOI: 10.1007/s10388-025-01116-9.

Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.

Sharma S Noncoding RNA Res. 2024; 9(4):1203-1221.

PMID: 39036603 PMC: 11259994. DOI: 10.1016/j.ncrna.2024.05.009.

Progress in the study of FOXO3a interacting with microRNA to regulate tumourigenesis development.

Sun L, Liu J, Bao D, Hu C, Zhao Y, Chen S Front Oncol. 2023; 13:1293968.

PMID: 37965449 PMC: 10641706. DOI: 10.3389/fonc.2023.1293968.

Genomic and Transcriptomic Research in the Discovery and Application of Colorectal Cancer Circulating Markers.

Ponomaryova A, Rykova E, Solovyova A, Tarasova A, Kostromitsky D, Dobrodeev A Int J Mol Sci. 2023; 24(15).

PMID: 37569782 PMC: 10419249. DOI: 10.3390/ijms241512407.

The role of miRNA in colorectal cancer diagnosis: A pilot study.

Zdralevic M, Raonic J, Popovic N, Vuckovic L, Rovcanin Dragovic I, Vukcevic B Oncol Lett. 2023; 25(6):267.

PMID: 37216163 PMC: 10193376. DOI: 10.3892/ol.2023.13853.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Chen C, Li L, Lodish H, Bartel D . MicroRNAs modulate hematopoietic lineage differentiation. Science. 2003; 303(5654):83-6. DOI: 10.1126/science.1091903. View

Croce C, Calin G . miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6-7. DOI: 10.1016/j.cell.2005.06.036. View

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View

Svoboda M, Izakovicova Holla L, Sefr R, Vrtkova I, Kocakova I, Tichy B . Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol. 2008; 33(3):541-7. View

Ng E, Chong W, Jin H, Lam E, Shin V, Yu J . Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-81. DOI: 10.1136/gut.2008.167817. View

Simons M, Raposo G . Exosomes--vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009; 21(4):575-81. DOI: 10.1016/j.ceb.2009.03.007. View

Aslam M, Taylor K, Pringle J, Jameson J . MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg. 2009; 96(7):702-10. DOI: 10.1002/bjs.6628. View

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X . Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2009; 127(1):118-26. DOI: 10.1002/ijc.25007. View

10.

Kanaan Z, Rai S, Eichenberger M, Roberts H, Keskey B, Pan J . Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256(3):544-51. DOI: 10.1097/SLA.0b013e318265bd6f. View

11.

Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L . Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398. PMC: 3435315. DOI: 10.1371/journal.pone.0044398. View

12.

Giraldez M, Lozano J, Ramirez G, Hijona E, Bujanda L, Castells A . Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin Gastroenterol Hepatol. 2012; 11(6):681-8.e3. DOI: 10.1016/j.cgh.2012.12.009. View

13.

Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X . A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2013; 136(1):152-61. DOI: 10.1002/ijc.28136. View

14.

Hofsli E, Sjursen W, Prestvik W, Johansen J, Rye M, Trano G . Identification of serum microRNA profiles in colon cancer. Br J Cancer. 2013; 108(8):1712-9. PMC: 3668463. DOI: 10.1038/bjc.2013.121. View

15.

Luo X, Stock C, Burwinkel B, Brenner H . Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One. 2013; 8(5):e62880. PMC: 3653912. DOI: 10.1371/journal.pone.0062880. View

16.

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y . Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013; 105(12):849-59. PMC: 3687369. DOI: 10.1093/jnci/djt101. View

17.

Hannafon B, Ding W . Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013; 14(7):14240-69. PMC: 3742242. DOI: 10.3390/ijms140714240. View

18.

Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q . Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2013; 25(3):346-52. DOI: 10.1097/CAD.0000000000000049. View

19.

Ge Q, Zhou Y, Lu J, Bai Y, Xie X, Lu Z . miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014; 19(2):1568-75. PMC: 6271968. DOI: 10.3390/molecules19021568. View

20.

Banzhaf-Strathmann J, Edbauer D . Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell Commun Signal. 2014; 12:30. PMC: 4011766. DOI: 10.1186/1478-811X-12-30. View